Drug Sponsors

Mallinckrodt to acquire Stratatech

Monday, August 15, 2016

Mallinckrodt, a global specialty pharmaceutical company, has entered into a merger agreement with Stratatech, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft regenerative skin tissue and a technology platform for genetically enhanced skin tissues. Financial terms of the transaction were not disclosed.

[Read More]

Myriad to acquire Assurex Health

Thursday, August 4, 2016

Myriad Genetics, a leader in molecular diagnostics and personalized medicine, has signed a definitive agreement to acquire Assurex Health, a global leader in genetic testing for psychotropic medicine selection, for $225 million upfront with the potential for $185 million in additional performance-based milestones. Assurex generated revenue of more than $60 million and tested more than 150,000 patients in Myriad’s fiscal year 2016.

[Read More]

BTC Network rebrands, acquires Novex Clinical Research

Tuesday, August 2, 2016

BTC Network, a fully integrated network of clinical research sites in the U.S., has strengthened its site operations with the recent acquisition of Novex Clinical Research, a multi-specialty research practice in New Bedford, Massachusetts. As a result of the deal, Novex Clinical Research will be the first clinical research site to be owned and operated under the BTC Network umbrella. It will strengthen BTC Network’s expertise and commitment to therapeutic areas such as psychiatry, neurology, pain, and internal medicine.

[Read More]

Takeda refocuses R&D, concentrating in Japan and the U.S.

Monday, August 1, 2016

Takeda Pharmaceutical plans to accelerate the R&D organization transformation by refocusing on three key therapeutic areas—Oncology, Gastroenterology (GI) and Central Nervous System (CNS), plus Vaccines, and concentrating R&D activities in Japan and the U.S. This transformation is critical to provide the company with the necessary organizational and financial flexibility to drive innovation, enhance partnerships, and improve R&D productivity for long-term, sustainable growth. Takeda will optimize its R&D sites globally.

[Read More]

BioAdvance commits $2.9M to 15 life sciences companies

Monday, August 1, 2016

BioAdvance announced that during the past 12 months it added nine new companies and technologies to its portfolio and made follow-on investments in six of its existing companies. Overall, these investments represent a $2.9 million commitment to the success and growth of life science companies and to this region.

[Read More]